These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 20831292)

  • 1. The economics of comparative effectiveness studies: societal and private perspectives and their implications for prioritizing public investments in comparative effectiveness research.
    Meltzer D; Basu A; Conti R
    Pharmacoeconomics; 2010; 28(10):843-53. PubMed ID: 20831292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Private manufacturers' thresholds to invest in comparative effectiveness trials.
    Basu A; Meltzer D
    Pharmacoeconomics; 2012 Oct; 30(10):859-68. PubMed ID: 22901018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the long-term impact of public investments in comparative effectiveness research: conceptual framework and lessons learned.
    Rich EC; Esposito D; Kimmey LD; Valenzano CS; Yong PL
    J Comp Eff Res; 2014 Nov; 3(6):657-66. PubMed ID: 25494572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness research in the United States: a progress report.
    Sullivan SD; Carlson JJ; Hansen RN
    J Med Econ; 2013; 16(2):295-7. PubMed ID: 23227997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAYER PERSPECTIVES ON FUTURE ACCEPTABILITY OF COMPARATIVE EFFECTIVENESS AND RELATIVE EFFECTIVENESS RESEARCH.
    Moloney R; Mohr P; Hawe E; Shah K; Garau M; Towse A
    Int J Technol Assess Health Care; 2015 Jan; 31(1-2):90-8. PubMed ID: 26168804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of HER2/Neu testing in breast cancer.
    Trosman JR; Weldon CB; Schink JC; Gradishar WJ; Benson AB
    J Comp Eff Res; 2013 Jul; 2(4):461-77. PubMed ID: 24236686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness research as choice architecture: the behavioral law and economics solution to the health care cost crisis.
    Korobkin R
    Mich Law Rev; 2014 Feb; 112(4):523-74. PubMed ID: 24446572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health technology assessment and comparative effectiveness research: a pharmaceutical industry perspective.
    Hao Y; Thomas A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):447-54. PubMed ID: 23977973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prioritizing comparative effectiveness research for cancer diagnostics using a regional stakeholder approach.
    Klein G; Gold LS; Sullivan SD; Buist DS; Ramsey S; Kreizenbeck K; Snell K; Loggers ET; Gifford J; Watkins JB; Kessler L
    J Comp Eff Res; 2012 May; 1(3):241-55. PubMed ID: 23105966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. It is important to note that RWD will never replace the more traditional and more robust RCT data; however, the emerging trend is to incorporate data that are more generalizable. Introduction.
    Mullins CD; Sanchez RJ
    J Manag Care Pharm; 2011; 17(9 Suppl A):S03-4. PubMed ID: 22074667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Looking at CER from the pharmaceutical industry perspective.
    Dubois RW
    J Manag Care Pharm; 2012 May; 18(4 Suppl A):S9-12. PubMed ID: 22578212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of comparative effectiveness research in drug coverage and pricing decisions: a six-country comparison.
    Sorenson C
    Issue Brief (Commonw Fund); 2010 Jul; 91():1-14. PubMed ID: 20614655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of comparative effectiveness research on interventional pain management: evolution from Medicare Modernization Act to Patient Protection and Affordable Care Act and the Patient-Centered Outcomes Research Institute.
    Manchikanti L; Falco FJ; Benyamin RM; Helm S; Parr AT; Hirsch JA
    Pain Physician; 2011; 14(3):E249-82. PubMed ID: 21587337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maximizing the clinical utility of comparative effectiveness research.
    Umscheid CA
    Clin Pharmacol Ther; 2010 Dec; 88(6):876-9. PubMed ID: 20962776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facts, fallacies, and politics of comparative effectiveness research: Part I. Basic considerations.
    Manchikanti L; Falco FJ; Boswell MV; Hirsch JA
    Pain Physician; 2010; 13(1):E23-54. PubMed ID: 20119474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The case for a comparative, value-based alternative to the patient-centered outcomes research model for comparative effectiveness research.
    Marko NF; Weil RJ
    Neurosurg Focus; 2012 Jul; 33(1):E8. PubMed ID: 22746240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of comparative effectiveness research in Asia, Europe, and North America.
    Patel I; Rarus R; Tan X; Lee EK; Guy J; Ahmad A; Chang J
    Indian J Pharmacol; 2015; 47(6):585-93. PubMed ID: 26729947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leveraging observational registries to inform comparative effectiveness research.
    Shah BR; Drozda J; Peterson ED
    Am Heart J; 2010 Jul; 160(1):8-15. PubMed ID: 20598966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A tall order on a tight timeframe: stakeholder perspectives on comparative effectiveness research using electronic clinical data.
    Holve E; Lopez MH; Scott L; Segal C
    J Comp Eff Res; 2012 Sep; 1(5):441-51. PubMed ID: 24236421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.